AstraZeneca’s (AZN) “Buy” Rating Reiterated at Shore Capital

Shore Capital reiterated their buy rating on shares of AstraZeneca (LON:AZN) in a research note released on Thursday, Marketbeat Ratings reports.

Other equities research analysts also recently issued reports about the stock. Barclays reiterated an overweight rating and set a £125 ($161.67) price objective on shares of AstraZeneca in a research note on Monday, April 8th. Deutsche Bank Aktiengesellschaft restated a hold rating and issued a £110 ($142.27) target price on shares of AstraZeneca in a research note on Tuesday, June 18th. JPMorgan Chase & Co. reaffirmed an overweight rating on shares of AstraZeneca in a research report on Tuesday, June 4th. Jefferies Financial Group lifted their price target on shares of AstraZeneca from GBX 71 ($0.92) to GBX 74 ($0.96) and gave the stock a hold rating in a research note on Tuesday, July 2nd. Finally, Citigroup reissued a buy rating on shares of AstraZeneca in a report on Tuesday, May 28th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of Moderate Buy and an average target price of £105.53 ($136.49).

AstraZeneca Stock Performance

LON:AZN opened at £121.80 ($157.53) on Thursday. The company has a market cap of £188.79 billion, a P/E ratio of 3,903.85, a P/E/G ratio of 0.97 and a beta of 0.16. The firm’s 50 day moving average is £122.73 and its two-hundred day moving average is £112.96. AstraZeneca has a fifty-two week low of GBX 9,461 ($122.36) and a fifty-two week high of £127.04 ($164.30). The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 92.51.

AstraZeneca Cuts Dividend

The business also recently disclosed a dividend, which will be paid on Monday, September 9th. Stockholders of record on Thursday, August 8th will be paid a dividend of GBX 77.60 ($1.00) per share. This represents a dividend yield of 0.64%. The ex-dividend date is Thursday, August 8th. AstraZeneca’s dividend payout ratio is presently 7,307.69%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.